dc.contributor.author | Leblebicioglu H. | |
dc.contributor.author | Bayirli D. | |
dc.contributor.author | Esen S. | |
dc.contributor.author | Sunbul M. | |
dc.contributor.author | Eroglu C. | |
dc.date.accessioned | 2020-06-21T09:14:52Z | |
dc.date.available | 2020-06-21T09:14:52Z | |
dc.date.issued | 2002 | |
dc.identifier.issn | 1476-0711 | |
dc.identifier.uri | https://doi.org/10.1186/1476-0711-1-3 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12712/2553 | |
dc.description | PubMed: 12437778 | en_US |
dc.description.abstract | Hepatitis C virus (HCV) infection becomes chronic in about 85 % of individuals as demonstrated by the persistence of HCV. It is necesseray to treat acute hepatitis C infection. Interferon-?is generally used for the treatment of acute HCV infection. Case presentation: A 55-year-old woman with a history of fatique and icter was diagnosed as acute hepatitis C virus infection. She was treated with interferon-? 2b 3 million unite sc three times in a week and ribavirin 1000 mg daily for 6 months. Within 2 weeks of therapy, the alanine aminotransferase (ALT) had became normal. At the end of the 3 months of therapy, HCV RNA was negative and remained negative 6 months after the end of interferon treatment (sustained response). Conclusion: This report suggests that interferon-? 2b and ribavirin may have a role in treatment of acute hepatitis C virus infection. © 2002 Leblebicioglu et al; licensee BioMed Central Ltd. | en_US |
dc.language.iso | eng | en_US |
dc.relation.isversionof | 10.1186/1476-0711-1-3 | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.title | Treatment of acute hepatitis C virus infection with interferon-? 2b and ribavirin: Case report and review of the literature | en_US |
dc.type | article | en_US |
dc.contributor.department | OMÜ | en_US |
dc.identifier.volume | 1 | en_US |
dc.relation.journal | Annals of Clinical Microbiology and Antimicrobials | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |